{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:30:31Z","timestamp":1761971431749,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.jocn.2012.02.007","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T11:58:45Z","timestamp":1340798325000},"page":"17-22","source":"Crossref","is-referenced-by-count":26,"title":["Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas"],"prefix":"10.1016","volume":"20","author":[{"given":"Andrew","family":"Yew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Trang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Spasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winward","family":"Choy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2012.02.007_b0005","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2011.2.FOCUS1116","article-title":"The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments","volume":"30","author":"Choy","year":"2011","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2012.02.007_b0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1130-1473(03)70510-7","article-title":"Meningioma: a model of cytogenetic evolution in tumoral initiation and progresion","volume":"14","author":"Lopez-Gines","year":"2003","journal-title":"Neurocirugia (Astur)"},{"key":"10.1016\/j.jocn.2012.02.007_b0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000056986","article-title":"Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases","volume":"93","author":"Zang","year":"2001","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.jocn.2012.02.007_b0025","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1073\/pnas.94.26.14719","article-title":"Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression","volume":"94","author":"Weber","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocn.2012.02.007_b0030","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.humpath.2005.02.006","article-title":"Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas","volume":"36","author":"Liu","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","article-title":"Pathological classification and molecular genetics of meningiomas","volume":"99","author":"Mawrin","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1750-3639.2002.tb00429.x","article-title":"Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas","volume":"12","author":"Buschges","year":"2002","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0045","first-page":"938","article-title":"Vascular endothelial growth factor, hepatocyte growth factor\/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy","volume":"46","author":"Lamszus","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jnen\/63.4.275","article-title":"Meningioma pathology, genetics, and biology","volume":"63","author":"Lamszus","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jocn.2012.02.007_b0055","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0046-8177(97)90029-0","article-title":"Telomerase activity in ordinary meningiomas predicts poor outcome","volume":"28","author":"Langford","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3171\/jns.2000.92.5.0832","article-title":"Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression","volume":"92","author":"Simon","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnen\/60.6.628","article-title":"Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications","volume":"60","author":"Cai","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jocn.2012.02.007_b0070","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1200\/JCO.2003.07.156","article-title":"New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology","volume":"21","author":"Maillo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1750-3639.2002.tb00433.x","article-title":"A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas","volume":"12","author":"Perry","year":"2002","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostrom","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00381-002-0562-7","article-title":"Telomerase in brain tumors","volume":"18","author":"Falchetti","year":"2002","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.jocn.2012.02.007_b0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2119\/molmed.2010.00005","article-title":"Gene expression profiling of the hedgehog signaling pathway in human meningiomas","volume":"16","author":"Laurendeau","year":"2010","journal-title":"Mol Med"},{"key":"10.1016\/j.jocn.2012.02.007_b0095","first-page":"4696","article-title":"Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression","volume":"55","author":"Simon","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2012.02.007_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(06)70625-1","article-title":"Histological classification and molecular genetics of meningiomas","volume":"5","author":"Riemenschneider","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2012.02.007_b0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1593\/neo.08356","article-title":"Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas","volume":"10","author":"Baia","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.jocn.2012.02.007_b0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcp.10208","article-title":"HES and HERP families: multiple effectors of the Notch signaling pathway","volume":"194","author":"Iso","year":"2003","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jocn.2012.02.007_b0115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3171\/jns.1996.84.5.0847","article-title":"Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma","volume":"84","author":"Harada","year":"1996","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/gcc.2870130311","article-title":"Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas","volume":"13","author":"Merel","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-004-2749-0","article-title":"Molecular pathogenesis of meningiomas","volume":"70","author":"Perry","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0130","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2012.02.007_b0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.humpath.2005.12.020","article-title":"Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study","volume":"37","author":"Loussouarn","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0140","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1002\/cncr.26065","article-title":"Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by (111) indium-octreotide imaging","volume":"117","author":"Alexandru","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1227\/00006123-199207000-00002","article-title":"Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma","volume":"31","author":"Kallio","year":"1992","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection","volume":"62","author":"Mirimanoff","year":"1985","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0155","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/1097-0142(19941215)74:12<3176::AID-CNCR2820741217>3.0.CO;2-N","article-title":"MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management","volume":"74","author":"Ohta","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.02.007_b0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1005853720926","article-title":"Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy","volume":"37","author":"Dziuk","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/jnnp.2007.121582","article-title":"Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features","volume":"79","author":"Yang","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.02.007_b0175","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3171\/jns.1997.86.5.0793","article-title":"Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases","volume":"86","author":"Palma","year":"1997","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0180","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M","article-title":"\u201cMalignancy\u201d in meningiomas: a clinicopathologic study of 116 patients, with grading implications","volume":"85","author":"Perry","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-009-9934-0","article-title":"WHO grade II and III meningiomas: a study of prognostic factors","volume":"95","author":"Durand","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1006434124794","article-title":"Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy","volume":"48","author":"Hug","year":"2000","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02688690802308687","article-title":"Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine?","volume":"22","author":"Marcus","year":"2008","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0200","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ijrobp.2007.12.020","article-title":"Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network","volume":"71","author":"Pasquier","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jocn.2012.02.007_b0205","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3171\/2010.3.JNS091807","article-title":"Factors affecting outcome following treatment of patients with cavernous sinus meningiomas","volume":"113","author":"Sughrue","year":"2010","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0210","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1227\/01.NEU.0000170980.47582.A5","article-title":"Diagnosis and treatment of atypical and anaplastic meningiomas: a review","volume":"57","author":"Modha","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0215","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.prp.2010.09.002","article-title":"The significance of Ki-67\/MIB-1 labeling index in human meningiomas: a literature study","volume":"206","author":"Abry","year":"2010","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jocn.2012.02.007_b0220","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0046-8177(98)90010-7","article-title":"MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors","volume":"29","author":"Abramovich","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-0320(19990615)38:3<118::AID-CYTO5>3.0.CO;2-J","article-title":"Proportion of S-phase tumor cells measured by flow cytometry is an independent prognostic factor in meningioma tumors","volume":"38","author":"Maillo","year":"1999","journal-title":"Cytometry"},{"key":"10.1016\/j.jocn.2012.02.007_b0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2184.2005.00325.x","article-title":"The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas","volume":"38","author":"Maes","year":"2005","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jocn.2012.02.007_b0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s004280100466","article-title":"Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo","volume":"439","author":"Cabuy","year":"2001","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jocn.2012.02.007_b0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3171\/jns.2004.100.2.0303","article-title":"Prognostic value of allelic losses and telomerase activity in meningiomas","volume":"100","author":"Leuraud","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0245","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3171\/jns.2007.106.6.1034","article-title":"Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma","volume":"106","author":"Smith","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0250","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1748-717X-5-46","article-title":"Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma","volume":"5","author":"Wernicke","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0255","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3171\/jns.2001.94.2.0293","article-title":"Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells","volume":"94","author":"Johnson","year":"2001","journal-title":"J Neurosurg"},{"issue":"Suppl. 1","key":"10.1016\/j.jocn.2012.02.007_b0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1054\/jocn.2001.0877","article-title":"Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas","volume":"8","author":"Yang","year":"2001","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2012.02.007_b0265","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1172\/JCI0214940","article-title":"Putting the neo into neoangiogenesis","volume":"109","author":"Moore","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2012.02.007_b0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1440-1789.2010.01105.x","article-title":"Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas","volume":"30","author":"Barresi","year":"2010","journal-title":"Neuropathology"},{"key":"10.1016\/j.jocn.2012.02.007_b0275","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1440-1789.2008.00902.x","article-title":"Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas","volume":"28","author":"Barresi","year":"2008","journal-title":"Neuropathology"},{"key":"10.1016\/j.jocn.2012.02.007_b0280","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00401-007-0251-4","article-title":"Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas","volume":"114","author":"Barresi","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0285","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00428-009-0757-3","article-title":"Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density","volume":"454","author":"Barresi","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jocn.2012.02.007_b0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijc.2910460106","article-title":"Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products","volume":"46","author":"Maxwell","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02478918","article-title":"Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression","volume":"18","author":"Nagashima","year":"2001","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.jocn.2012.02.007_b0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ijc.2910460504","article-title":"Expression of PDGF beta-receptors in human meningioma cells","volume":"46","author":"Wang","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0305","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1005872718547","article-title":"Platelet-derived growth factor in human brain tumors","volume":"35","author":"Kirsch","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0310","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3171\/jns.1996.84.5.0852","article-title":"Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor","volume":"84","author":"Todo","year":"1996","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0315","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01\u201308)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0320","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/FOC-07\/10\/E9","article-title":"Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition","volume":"23","author":"Gupta","year":"2007","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.jocn.2012.02.007_b0325","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3322\/caac.20075","article-title":"Angiogenesis inhibitors: current strategies and future prospects","volume":"60","author":"Cook","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jocn.2012.02.007_b0330","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2012.02.007_b0335","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","article-title":"Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab","volume":"22","author":"Goutagny","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0340","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/annonc\/mdq634","article-title":"Bevacizumab-induced regression of anaplastic meningioma","volume":"21","author":"Puchner","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0345","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/00006123-199706000-00029","article-title":"Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression","volume":"40","author":"Goldman","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0350","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/00006123-199705000-00027","article-title":"Meningiomas: role of vascular endothelial growth factor\/vascular permeability factor in angiogenesis and peritumoral edema","volume":"40","author":"Provias","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0355","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2012.02.007_b0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B","volume":"40","author":"Kaba","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jocn.2012.02.007_b0365","first-page":"2269","article-title":"Meningioma treated with interferon-alpha, evaluated with [(11)C]-l-methionine positron emission tomography","volume":"7","author":"Muhr","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2012.02.007_b0370","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3171\/jns.1997.86.1.0113","article-title":"Progesterone and estrogen receptors in meningiomas: prognostic considerations","volume":"86","author":"Hsu","year":"1997","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0375","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/07357900601062339","article-title":"Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma","volume":"24","author":"Grunberg","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jocn.2012.02.007_b0385","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0390","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3171\/jns.2001.94.3.0487","article-title":"Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice","volume":"94","author":"McCutcheon","year":"2001","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2012.02.007_b0395","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/eje.1.01825","article-title":"Effect of treatment with pegvisomant on meningioma growth in vivo","volume":"152","author":"Drake","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jocn.2012.02.007_b0400","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/B:NEON.0000013498.19981.55","article-title":"Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity","volume":"66","author":"Arena","year":"2004","journal-title":"J Neurooncol"},{"issue":"Suppl. 2","key":"10.1016\/j.jocn.2012.02.007_b0405","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1093\/annonc\/12.suppl_2.S131","article-title":"Neuroendocrine tumors in the brain","volume":"12","author":"Cavalla","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jocn.2012.02.007_b0410","first-page":"763","article-title":"Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas","volume":"46","author":"Henze","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jocn.2012.02.007_b0415","first-page":"1913","article-title":"Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma","volume":"39","author":"Klutmann","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jocn.2012.02.007_b0420","first-page":"237","article-title":"Clinical use of octreotide in unresectable meningiomas. A report of three cases","volume":"37","author":"Garcia-Luna","year":"1993","journal-title":"J Neurosurg Sci"},{"key":"10.1016\/j.jocn.2012.02.007_b0425","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586812001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586812001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:55:56Z","timestamp":1714103756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586812001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0967586812001233"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2012.02.007","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}